

#2/2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner: Not Yet Assigned

Sai P. Sunkara

Prior Art Unit: 1614

Serial No.: Not Yet Assigned

Filed: September 25, 1998

Title: **Method of Treating Cancer by
Conjunctive Therapy with 2'-
Halomethylidene Derivatives and a S-
Phase or M-Phase Specific Antineoplastic
Agent**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

SEPTEMBER 25, 1998

Date of Deposit

Signature

EM361641235 US



INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been

mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **13-2764**.


- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

The items listed with an asterisk on the attached PTO-1449 (modified) have been previously submitted by the examiner or the applicant in related applications of this series:

<u>Serial Numbers</u>	<u>Filing Date</u>	<u>Status</u>
08/967,190	10/29/97	Pending
08/834,589	04/07/97	Abandoned
08/537,170	09/28/95	Abandoned
08/435,240	05/05/95	Abandoned
08/358,662	12/19/94	Abandoned
08/285,618	08/03/94	Abandoned
08/182,313	01/14/94	Abandoned
08/098,769	07/28/93	Abandoned
08/023,160	02/25/93	Abandoned
07/866,399	04/10/92	Abandoned

Therefore, a copy of the reference(s) are not enclosed with this Information Disclosure Statement.

Respectfully submitted,



Mark C. Nelligan, Reg. No. 36,389
Attorney/Agent for Applicant

Hoechst Marion Roussel, Inc.
2110 East Galbraith Road
P. O. Box 156300
Cincinnati, Ohio 45215-6300
Telephone (908) 231-2388
Telefax (513) 948-7961
(513) 948-4681

PATENT

Sheet 1 of 1

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. MO1660J US	SERIAL NO. Not Yet Assigned
	APPLICANT SAI P. SUNKARA	
	FILING DATE September 25, 1998	PREVIOUS GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	*		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	*		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	*	B.1	0	3	7	2	2	6	8	06/13/90	EP				

OTHER DOCUMENTS

EXAMINER INITIALS	*		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.												
	*	C.1	McCarthy, et al. <u>J. Am. Chem. Soc.</u> 113(19):7439-40, 1991												
	*	C.2	Carter, et al. <u>Chemotherapy of Cancer</u> , 2 nd ed., 76-83, and 186, 1981												
	*	C.3	Sunkara, et al. <u>Proceedings 83rd Ann. Mtg. Of the American Assoc. for Cancer Res.</u> Vol. 33, No.3088"517, 1992												
	*	C.4	Kobayashky, et al. <u>Pharmaceutical Research</u> , Vol. 4:181-183, 1984												

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Note: Asterisk (*) item(s) have been previously cited in a related application(s) either by the applicant or by the USPTO and therefore copies of the reference(s) are not being submitted.